AnaptysBio Files 8-K Report

TL;DR

ANAB filed an 8-K, likely an update, check for details.

AI Summary

On December 11, 2024, AnaptysBio, Inc. filed an 8-K report. The filing indicates an 'Other Event' and does not provide specific details on material agreements, acquisitions, or financial results within the provided text. The report was filed as of December 11, 2024.

Why It Matters

This filing signifies a corporate update from AnaptysBio, Inc. to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing header and does not contain specific financial or operational details that would indicate a high-risk event.

Key Players & Entities

• ANAPTYSBIO, INC (company) — Registrant
• 10770 Wateridge Circle, Suite 210, San Diego, CA 92121 (location) — Principal Executive Offices
• December 11, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ANAB The Nasdaq Stock Marke
• $415 million — and investments to total approximately $415 million as of December 31, 2024. The Company be

Filing Documents

• anab-20241211.htm (8-K) — 26KB
• 0001370053-24-000067.txt ( ) — 189KB
• anab-20241211.xsd (EX-101.SCH) — 2KB
• anab-20241211_def.xml (EX-101.DEF) — 9KB
• anab-20241211_lab.xml (EX-101.LAB) — 29KB
• anab-20241211_pre.xml (EX-101.PRE) — 20KB
• anab-20241211_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On December 11, 2024, AnaptysBio, Inc. (the "Company") announced the results of Phase 2B Trial of ANB032, a BLTA agonist, and provided an estimate of the Company's year-end cash reserves for the 2024 fiscal year. Phase 2b Trial of ANB032 Investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. ANB032 was well tolerated with no safety signals observed. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe AD. The study enrolled 201 patients with a mean baseline EASI score of 27.3 in the U.S., Canada, Europe, Australia and New Zealand, who were either biologics nave (n=168) or biologics experienced (n=33), defined as having received treatment with dupilumab or other IL-13 therapies. Patients were randomized to receive for 12 weeks either 100mg of subcutaneous ANB032 every four weeks (Q4W), 400mg every four weeks (Q4W) or 400mg every two weeks (Q2W), or placebo. The primary and secondary endpoints were assessed at Week 14. Regardless of prior treatment experience, ANB032 did not meet the primary endpoint of the proportion of patients who achieved at least a 75% improvement from baseline in Eczema Area and Severity Index score (EASI-75), or any of the secondary endpoints at Week 14, including EASI-90, mean change in baseline EASI or a 4-point reduction in itch severity as measured by the peak Pruritus Numerical Rating Scale (PNRS) versus placebo. Absolute response rates on key endpoints in patients treated with ANB032 approached the minimum target product profile with durable off-drug responses; however, higher placebo rates outside of the historical norm, particularly in the U.S., were observed. ANB032 was well tolerated across all doses with no safety signals

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANAPTYSBIO, INC. Date: December 11, 2024 By: /s/Eric Loumeau Name: Eric Loumeau Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR